Glioma tumors that are IDH-mutant and IDH-wildtype are biologically distinct, differing in their chromatin structure, gene expression, disease development and progression, and even prognosis, where IDH-wildtype status is associated with worse overall survival [15]. This evidence concerns the gene IDH2 and central nervous system cancer.